Entremed (ENMD): Neil made some interesting comments rega...

Reply Private New

Replies (2) Next 10 Prev Next

Send PM Follow Ignore

Followers	1
Posts	77
Boards Moderated	0
Alias Born	04/10/2004

potsy7264

Re: None

Tuesday, 04/27/2004 5:16:04 PM

Tuesday, April 27, 2004 5:16:04 PM

Neil made some interesting comments regarding the multiple myeloma phase II trial to the Rodman analyst. These comments have been overlooked by everyone.
Panzem is in Phase II for multiple myeloma at this time. During the CC Neil mentioned that they are currently working with the FDA to get the new formulation into this trial. If this is true we won't be waiting for 2005 to see clinical results and possible fast track approval like Avastin. Genentech's drug Avastin won approval from the FDA for one application which was colorectal cancer. This was after fast track approval for the same application. Panzem only need to be approved for one application. I did hear correctly didn't I?

Dec. 7th
"Phase II data demonstrating that Panzem(R) is well tolerated and stabilized disease in patients with plateau or relapsed multiple myeloma, the second most prevalent form of blood cancer among Americans. EntreMed plans to continue evaluation in these patients using a new formulation of Panzem(R) designed to increase and prolong exposure to this drug candidate."

http://investor.entremed.com/ireye/ir_site.zhtml?ticker=ENMD&script=460&layout=-6&item_i....